Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake.

Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has reached a 52-week low, dipping to $114.41, as investors navigate a challenging market environment. According to InvestingPro data, the company ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. The partnership will leverage AMD Instinct accelerators and ROCm software ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software “We are proud ...

Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...

A significant factor is the strategic collaboration with Advanced Micro Devices (AMD), which is expected to enhance AbSci’s AI-based antibody development capabilities. AMD’s investment and ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake. AMD, which is based in Santa Clara ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...